Taps Coogan – September 22nd, 2023

The following article is reposted from Statista.com:

The rate of people dying of Alzheimer’s disease in the United States more than doubled between the years 2000 and 2019, according to the Alzheimer’s Association’s latest report. Where an average of 17.6 people per 100,000 died from the form of dementia at the turn of the millennium, the figure had climbed to 37 per 100,000 people nearly two decades later.

According to the Alzheimer’s Association, this is likely the result of an aging population, since age is the predominant risk factor for Alzheimer’s dementia. However, they note, it could also reflect a rise in the number of formal diagnoses of the disease or even in the number of physicians who are reporting Alzheimer’s as a cause of death. 

The charity’s analysts forecast that by 2025, the number of people aged 65+ with Alzheimer’s dementia in the U.S. could reach 7.2 million, and up to 13.8 million by 2060, if there were to be no medical breakthroughs in that time to prevent, slow or cure the disease. On that note, pharmaceutical companies have a number of drugs in development, targeting different symptoms, from inflammation to synaptic plasticity/neuroprotection pathways.